SPRINT研究中尿表皮生长因子与CKD患者肾脏及心血管结局的关联
本研究在2346例eGFR<60 ml/min/1.73 m²的SPRINT参与者中测量基线uEGF水平,分析其与每年eGFR变化、eGFR下降≥30%、CVD和全因死亡的关系。结果发现,uEGF每降低50%与eGFR每年多下降0.74%及eGFR下降≥30%风险升高1.17倍独立相关,但与ESKD、AKI、CVD和全因死亡无显著独立关联。
要点
- 在高血压合并CKD人群中,较低基线uEGF与更快的eGFR下降独立相关。
- uEGF与ESKD、AKI、CVD及全因死亡的关联在调整基线尿白蛋白和eGFR后不显著。
- uEGF可能作为CKD肾功能进展的候选生物标志物,但需进一步验证。
核心结论
- 在高血压合并CKD的成人中,较低基线uEGF浓度与更快的eGFR下降独立相关,但与ESKD、AKI、CVD和全因死亡无显著独立关联。
研究设计与样本
- 研究纳入2346例SPRINT试验中eGFR<60 ml/min/1.73 m²的参与者,测量基线uEGF水平。
- 采用线性混合效应模型分析uEGF与每年eGFR变化的关系,Cox比例风险模型分析其与eGFR下降≥30%、CVD和全因死亡的关系,Fine-Gray法分析AKI和ESKD。
主要发现
- 基线平均年龄73±9岁,平均eGFR 46±11 ml/min/1.73 m²,尿白蛋白肌酐比中位数15 mg/g(四分位距7-49)。
- 在多变量调整(含基线尿白蛋白和eGFR)后,uEGF每降低50%与eGFR每年多下降0.74%(95%CI:0.29-1.19)及eGFR下降≥30%风险升高1.17倍(95%CI:1.00-1.36)相关。
- 较低uEGF与ESKD、AKI、CVD和全因死亡风险升高有关,但调整基线尿白蛋白和eGFR后未达统计学显著性。
临床怎么用
- 在高血压合并CKD患者中,可考虑检测uEGF以辅助评估肾功能下降风险。
- uEGF对心血管结局和死亡的预测价值在调整基线肾功能和蛋白尿后不显著,不宜单独用于这些结局的风险分层。
局限性
- 研究仅纳入SPRINT试验中eGFR<60 ml/min/1.73 m²的高血压患者,结果外推需谨慎。
- uEGF与ESKD、AKI、CVD和全因死亡的关联在调整基线尿白蛋白和eGFR后不显著,不能排除残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Urine epidermal growth factor (uEGF) has been found to be inversely associated with kidney function loss, whereas its associations with cardiovascular disease (CVD) and mortality have not been studied. METHODS: We measured baseline uEGF levels among 2346 Systolic Blood Pressure Intervention Trial (SPRINT) participants with an estimated glomerular filtration rate (eGFR) < 60 ml/min per 1.73 m2. A linear mixed-effects model was used to investigate the associations of uEGF with the annual eGFR change; Cox proportional hazards regression models were used to analyze its associations with the ≥30% eGFR decline, CVD, and all-cause mortality outcomes. To account for the competing risk of death, the Fine and Gray method was utilized for acute kidney injury (AKI) and end-stage kidney disease (ESKD) outcomes. RESULTS: At baseline, the study participants had mean age of 73 ± 9 years, mean eGFR of 46 ± 11 ml/min per 1.73 m2, and median urine albumin-to-creatinine ratio (UACR) of 15 mg/g (interquartile range: 7-49). In the multivariable-adjusted analysis including baseline urine albumin and eGFR, each 50% lower uEGF concentration was associated with 0.74% (95% confidence interval [CI]: 0.29-1.19) per year faster decline in eGFR and 1.17 times higher risk of ≥30% eGFR decline (95% CI: 1.00-1.36). Lower uEGF concentrations were found to be associated with increased risks of ESKD, AKI, CVD, and all-cause mortality; however, these associations did not reach statistical significance when the models were controlled for baseline urine albumin and eGFR. CONCLUSION: Among hypertensive adults with chronic kidney disease (CKD), lower baseline uEGF concentration was associated with faster eGFR decline independent of baseline albuminuria and eGFR; but not with ESKD, AKI, CVD, and all-cause mortality.
引用
- Postalcioglu M, Katz R, Ascher SB, et al. Associations of Urine Epidermal Growth Factor With Kidney and Cardiovascular Outcomes in Individuals With CKD in SPRINT. Kidney Int Rep. 2024. PMID: 39534189. doi:10.1016/j.ekir.2024.08.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。